메뉴 건너뛰기




Volumn 17, Issue 2, 2013, Pages 194-204

Safety aspects of protease inhibitors for chronic hepatitis C: Adverse events and drug-to-drug interactions

Author keywords

Adverse events; Drug interactions; Hepatitis C; Protease inhibitors

Indexed keywords

AMIODARONE; ANTIHISTAMINIC AGENT; ATAZANAVIR PLUS RITONAVIR; ATORVASTATIN; BOCEPREVIR; CLARITHROMYCIN; COLCHICINE; CORTICOSTEROID; DARUNAVIR PLUS RITONAVIR; DOMPERIDONE; DROSPIRENONE; EFAVIRENZ; ERYTHROPOIETIN; FOSAMPRENAVIR PLUS RITONAVIR; LOPINAVIR PLUS RITONAVIR; MEVINOLIN; PEGINTERFERON; PLACEBO; PRAVASTATIN; RALTEGRAVIR; RIBAVIRIN; RIFAMPICIN; RITONAVIR; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; TELAPREVIR; TENOFOVIR; TRAZODONE; UNINDEXED DRUG; ZIDOVUDINE;

EID: 84876738261     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/j.bjid.2012.10.010     Document Type: Short Survey
Times cited : (16)

References (37)
  • 1
    • 80053339008 scopus 로고    scopus 로고
    • An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
    • Ghany M.G., Nelson D.R., Strade D.B., Thomas D.L., Seeff L.B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54:1433-1434.
    • (2011) Hepatology , vol.54 , pp. 1433-1434
    • Ghany, M.G.1    Nelson, D.R.2    Strade, D.B.3    Thomas, D.L.4    Seeff, L.B.5
  • 2
    • 0345188811 scopus 로고    scopus 로고
    • Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line
    • Lohmann V., Korner F., Koch J., et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285:110-113.
    • (1999) Science , vol.285 , pp. 110-113
    • Lohmann, V.1    Korner, F.2    Koch, J.3
  • 3
    • 23044437222 scopus 로고    scopus 로고
    • Complete replication of hepatitis C virus in cell culture
    • Lindenbach B.D., Evans M.J., Syder A.J., et al. Complete replication of hepatitis C virus in cell culture. Science 2005, 309:623-626.
    • (2005) Science , vol.309 , pp. 623-626
    • Lindenbach, B.D.1    Evans, M.J.2    Syder, A.J.3
  • 4
    • 81855220325 scopus 로고    scopus 로고
    • The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors
    • Kwo P.Y., Vinayek R. The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors. Gut Liver 2011, 5:406-417.
    • (2011) Gut Liver , vol.5 , pp. 406-417
    • Kwo, P.Y.1    Vinayek, R.2
  • 5
    • 34247895578 scopus 로고    scopus 로고
    • The hepatitis C viral life cycle as a target for new antiviral therapies
    • Pawlotsky J.M., Chevaliez S., McHutchison J.G. The hepatitis C viral life cycle as a target for new antiviral therapies. Gastroenterology 2007, 132:1979-1998.
    • (2007) Gastroenterology , vol.132 , pp. 1979-1998
    • Pawlotsky, J.M.1    Chevaliez, S.2    McHutchison, J.G.3
  • 6
    • 0033920795 scopus 로고    scopus 로고
    • Replication of hepatitis C virus
    • Bartenschlager R., Lohmann V. Replication of hepatitis C virus. J Gen Virol 2000, 81:1631-1648.
    • (2000) J Gen Virol , vol.81 , pp. 1631-1648
    • Bartenschlager, R.1    Lohmann, V.2
  • 7
    • 84876710927 scopus 로고    scopus 로고
    • Incivek (telaprevir) film coated tablets. Vertex. May. Available at [accessed April 12, 2012]
    • Incivek (telaprevir) film coated tablets. Vertex. May 2011. Available at [accessed April 12, 2012]. http://www.accessdata.fda.gov/drugsastda_docs/label/2011/201917lbl.pdf.
    • (2011)
  • 8
    • 84876744405 scopus 로고    scopus 로고
    • Victrelis (boceprevir) capsules. Merck. May. Available at: [accessed April 12, 2012].
    • Victrelis (boceprevir) capsules. Merck. May 2011. Available at: [accessed April 12, 2012]. http://www.accessdata.fda.gov/drugsastda_docs/label/2011/202258lbl.pdf.
    • (2011)
  • 9
    • 65449152185 scopus 로고    scopus 로고
    • Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
    • McHutchison J.G., Everson G.T., Gordon S.C., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009, 360:1827-1838.
    • (2009) N Engl J Med , vol.360 , pp. 1827-1838
    • McHutchison, J.G.1    Everson, G.T.2    Gordon, S.C.3
  • 10
    • 65449171953 scopus 로고    scopus 로고
    • Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
    • Hézode C., Forestier N., Dusheiko G., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009, 360:1839-1850.
    • (2009) N Engl J Med , vol.360 , pp. 1839-1850
    • Hézode, C.1    Forestier, N.2    Dusheiko, G.3
  • 11
    • 77956268467 scopus 로고    scopus 로고
    • Efficacy of boceprevir and NS3 protease inhibitor in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomized, multicentre phase 2 trial
    • Kwo P.Y., Lawitz E.J., McCone J., et al. Efficacy of boceprevir and NS3 protease inhibitor in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomized, multicentre phase 2 trial. Lancet 2010, 376:705-716.
    • (2010) Lancet , vol.376 , pp. 705-716
    • Kwo, P.Y.1    Lawitz, E.J.2    McCone, J.3
  • 12
    • 79959438789 scopus 로고    scopus 로고
    • Telaprevir for previously untreated chronic hepatitis C infection
    • Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C infection. N Engl J Med 2011, 364:2405-2416.
    • (2011) N Engl J Med , vol.364 , pp. 2405-2416
    • Jacobson, I.M.1    McHutchison, J.G.2    Dusheiko, G.3
  • 13
    • 79953173221 scopus 로고    scopus 로고
    • for SPRINT-2 investigators. Boceprevir for untreated chronic HCV genotype 1 infection.
    • Poordad F, McCone Jr. J, Bacon BR, et al.; for SPRINT-2 investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-206.
    • (2011) N Engl J Med. , vol.364 , pp. 1195-206
    • Poordad, F.1    McCone Jr., J.2    Bacon, B.R.3
  • 14
    • 84857368831 scopus 로고    scopus 로고
    • UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients
    • Ramachandran P., Fraser A., Agarwal K., et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther 2012, 35:647-662.
    • (2012) Aliment Pharmacol Ther , vol.35 , pp. 647-662
    • Ramachandran, P.1    Fraser, A.2    Agarwal, K.3
  • 15
    • 33644636312 scopus 로고    scopus 로고
    • Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease
    • Perni R.B., Almquist S.J., Byrn R.A., et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2006, 50:899-909.
    • (2006) Antimicrob Agents Chemother , vol.50 , pp. 899-909
    • Perni, R.B.1    Almquist, S.J.2    Byrn, R.A.3
  • 16
    • 84856267331 scopus 로고    scopus 로고
    • Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C
    • Tungol A., Rademacher K., Schafer J.A. Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C. J Manag Care Pharm 2011, 17:685-694.
    • (2011) J Manag Care Pharm , vol.17 , pp. 685-694
    • Tungol, A.1    Rademacher, K.2    Schafer, J.A.3
  • 17
    • 84876739567 scopus 로고    scopus 로고
    • U.S. Food and Drug Administration. Clinical pharmacology and biopharmaceutics review of telaprevir. Center for Drug Evaluation and Research. Available at: [accessed April 12, 2012].
    • U.S. Food and Drug Administration. Clinical pharmacology and biopharmaceutics review of telaprevir. Center for Drug Evaluation and Research. Available at: [accessed April 12, 2012]. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201917Orig1sClinPharmR.pdf.
  • 18
    • 84855244456 scopus 로고    scopus 로고
    • Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice
    • Hézode C. Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice. Liver Int 2012, 32(Suppl. 1):32-38.
    • (2012) Liver Int , vol.32 , Issue.SUPPL. 1 , pp. 32-38
    • Hézode, C.1
  • 19
    • 80053319159 scopus 로고    scopus 로고
    • Anemia had no effect on efficacy outcomes in treatment-naïve patients who received telaprevir-based regimen in the Advance and Illuminate phase 3 studies
    • Sulkowski M.S., Reddy R., Afdhal N.H., et al. Anemia had no effect on efficacy outcomes in treatment-naïve patients who received telaprevir-based regimen in the Advance and Illuminate phase 3 studies. J Hepatol 2011, 54:S195.
    • (2011) J Hepatol , vol.54
    • Sulkowski, M.S.1    Reddy, R.2    Afdhal, N.H.3
  • 20
    • 27544439540 scopus 로고    scopus 로고
    • Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases
    • Lübbe J., Kerl K., Negro F., et al. Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases. Br J Dermatol 2005, 153:1099.
    • (2005) Br J Dermatol , vol.153 , pp. 1099
    • Lübbe, J.1    Kerl, K.2    Negro, F.3
  • 21
    • 79959438789 scopus 로고    scopus 로고
    • Telaprevir for previously untreated chronic hepatitis C virus infection
    • Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416.
    • (2011) N Engl J Med , vol.364 , pp. 2405-2416
    • Jacobson, I.M.1    McHutchison, J.G.2    Dusheiko, G.3
  • 22
    • 79959381354 scopus 로고    scopus 로고
    • Telaprevir for retreatment of HCV infection
    • Zeuzem S., Andreone P., Pol S., et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417-2428.
    • (2011) N Engl J Med , vol.364 , pp. 2417-2428
    • Zeuzem, S.1    Andreone, P.2    Pol, S.3
  • 23
    • 77950817619 scopus 로고    scopus 로고
    • Telaprevir for previously treated chronic hepatitis C infection
    • McHutchison J., Manns M.P., Muir A.J., et al. Telaprevir for previously treated chronic hepatitis C infection. N Engl J Med 2010, 362:1292-1303.
    • (2010) N Engl J Med , vol.362 , pp. 1292-1303
    • McHutchison, J.1    Manns, M.P.2    Muir, A.J.3
  • 24
    • 79953173221 scopus 로고    scopus 로고
    • Boceprevir for untreated chronic HCV genotype 1 infection
    • Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
    • (2011) N Engl J Med , vol.364 , pp. 1195-1206
    • Poordad, F.1    McCone, J.2    Bacon, B.R.3
  • 25
    • 79953176289 scopus 로고    scopus 로고
    • for HCV RESPOND-2 investigators. Boceprevir for previously treated chronic HCV genotype 1 infection.
    • Bacon BR, Gordon SC, Lawitz E, et al.; for HCV RESPOND-2 investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-206.
    • (2011) N Engl J Med. , vol.364 , pp. 1195-206
    • Bacon, B.R.1    Gordon, S.C.2    Lawitz, E.3
  • 26
    • 84876743861 scopus 로고    scopus 로고
    • FDA Antiviral Drugs Advisory Committee. Telaprevir briefing document April 28, 2011. Available from: [accessed April 12, 2012].
    • FDA Antiviral Drugs Advisory Committee. Telaprevir briefing document April 28, 2011. Available from: ; 2011 [accessed April 12, 2012]. http://www.fda.gov/downloads/Advisory-Committees/MeetingMaterials/Drugs/AntiviralDrugsAdvisory-Committee/UCM252562.pdf.
    • (2011)
  • 27
    • 84855924980 scopus 로고    scopus 로고
    • Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals
    • Cacoub P., Mourliere M., Lübbe J., et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol 2012, 56:455-463.
    • (2012) J Hepatol , vol.56 , pp. 455-463
    • Cacoub, P.1    Mourliere, M.2    Lübbe, J.3
  • 28
    • 74549143149 scopus 로고    scopus 로고
    • Severe cutaneous adverse reactions to drugs (SCAR): definitions, diagnostic criteria, genetic predisposition
    • Roujeau J.C., Allanore L., Liss Y., et al. Severe cutaneous adverse reactions to drugs (SCAR): definitions, diagnostic criteria, genetic predisposition. Dermatol Sin 2009, 27:203-209.
    • (2009) Dermatol Sin , vol.27 , pp. 203-209
    • Roujeau, J.C.1    Allanore, L.2    Liss, Y.3
  • 29
    • 84859955001 scopus 로고    scopus 로고
    • Review and management of drug interactions with boceprevir and telaprevir
    • Kiser J., Burton J., Anderson P., et al. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012, 55:1620-1628.
    • (2012) Hepatology , vol.55 , pp. 1620-1628
    • Kiser, J.1    Burton, J.2    Anderson, P.3
  • 30
    • 84876696241 scopus 로고    scopus 로고
    • Drug interactions
    • Lippincott Williams & Wilkins, Philadelphia, R.A. Helmes, D.J. Quan, E.T. Herfindal, D.R. Gourley (Eds.)
    • Middleton R.K. Drug interactions. Textbook of therapeutics: drug and disease management 2006, 47-72. Lippincott Williams & Wilkins, Philadelphia. 8th ed. R.A. Helmes, D.J. Quan, E.T. Herfindal, D.R. Gourley (Eds.).
    • (2006) Textbook of therapeutics: drug and disease management , pp. 47-72
    • Middleton, R.K.1
  • 31
    • 84856869185 scopus 로고    scopus 로고
    • A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients
    • Wilby J., Greanya E., Ford J., et al. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol 2012, 11:179-185.
    • (2012) Ann Hepatol , vol.11 , pp. 179-185
    • Wilby, J.1    Greanya, E.2    Ford, J.3
  • 32
    • 80054908770 scopus 로고    scopus 로고
    • Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions
    • Seden K., Back D. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. Curr Opin HIV AIDS 2011, 6:514-526.
    • (2011) Curr Opin HIV AIDS , vol.6 , pp. 514-526
    • Seden, K.1    Back, D.2
  • 33
    • 77953501710 scopus 로고    scopus 로고
    • New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals
    • Seden K., Back D., Khoo S. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. Antimicrob Chemother 2010, 65:1079-1085.
    • (2010) Antimicrob Chemother , vol.65 , pp. 1079-1085
    • Seden, K.1    Back, D.2    Khoo, S.3
  • 34
    • 84876701716 scopus 로고    scopus 로고
    • World Health Organization Drospirenone-containing combined oral contraceptives: possible increased risk of blood clots
    • Available in, [assessed in May 15, 2012]
    • World Health Organization Drospirenone-containing combined oral contraceptives: possible increased risk of blood clots. WHO Pharm Newslett 2011, 6:5. Available in, [assessed in May 15, 2012]. http://www.who.int/medicines/publications/PharmNewsletter6_11/en/index.html.
    • (2011) WHO Pharm Newslett , vol.6 , pp. 5
  • 35
    • 84855252404 scopus 로고    scopus 로고
    • Telaprevir user's guide
    • Liapakis A., Jacobson I. Telaprevir user's guide. Liver Int 2012, 32(Suppl. 1):17-26.
    • (2012) Liver Int , vol.32 , Issue.SUPPL. 1 , pp. 17-26
    • Liapakis, A.1    Jacobson, I.2
  • 36
    • 84876706581 scopus 로고    scopus 로고
    • Micromedex Healthcare Series. Portal capes. Available in: [assessed in March, 14]
    • Micromedex Healthcare Series. Portal capes. Available in: [assessed in March, 14, 2012]. http://www.thomsonhc.com.ez27.periodicos.capes.gov.br/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/ABFE31/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/DDC7A0/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/evidencexpert.IntermediateToDocumentLink%3FdocId=2865%26contentSetId=31%26title=BOCEPREVIR%26servicesTitle=BOCEPREVIR.
    • (2012)
  • 37
    • 80052585054 scopus 로고    scopus 로고
    • Cytochrome P450 drug interactions
    • [Full update October 2009]
    • Cytochrome P450 drug interactions. Pharmacist's Letter/Prescriber's Letter 2006, 22(2):220233. [Full update October 2009].
    • (2006) Pharmacist's Letter/Prescriber's Letter , vol.22 , Issue.2 , pp. 220233


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.